Aclaris Therapeutics Inc
ACRS2.320USD
+0.050+2.20%
收盤 11/07, 16:00（美東）報價延遲15分鐘
251.35M總市值
虧損本益比TTM
關於 Aclaris Therapeutics Inc 公司
Aclaris Therapeutics, Inc. 是一家臨牀階段生物製藥公司，專注於開發免疫炎症疾病的新型候選藥物。該公司擁有一個多階段候選藥物組合，由強大的研發引擎提供支持，探索蛋白激酶調控。其部門包括治療和合同研究。治療部門專注於識別和開發療法，以滿足免疫炎症疾病的未滿足需求，並提供其知識產權的許可。合同研究部門提供實驗室服務。該公司的 KINect 藥物發現平臺與其臨牀前開發能力相結合，使其能夠識別和推進其可能獨立開發或與第三方合作開發的潛在候選藥物。該公司的候選藥物包括 ATI-1777、ATI-2138 和 Zunsemetinib。ATI-1777 是一種研究性局部軟 Janus 激酶或 JAK 1/3 抑制劑。
Aclaris Therapeutics Inc簡介
公司代碼ACRS
公司名稱Aclaris Therapeutics Inc
上市日期Oct 07, 2015
CEODr. Neal S. Walker
員工數量64
證券類型Ordinary Share
年結日Oct 07
公司地址701 Lee Road
城市WAYNE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編19087
電話14843247933
網址https://www.aclaristx.com/
公司代碼ACRS
上市日期Oct 07, 2015
CEODr. Neal S. Walker
Aclaris Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. James (Jim) Loerop
Mr. James (Jim) Loerop
Chief Business Officer
Chief Business Officer
103.31K
+21.18%
Mr. Christopher P. Molineaux
Mr. Christopher P. Molineaux
Lead Independent Director
Lead Independent Director
57.96K
+9.02%
Mr. William Douglas Humphries
Mr. William Douglas Humphries
Independent Director
Independent Director
33.52K
+16.68%
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Independent Director
Independent Director
21.75K
+28.26%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
17.32K
+38.27%
Dr. Andrew N. (Drew) Schiff, M.D.
Dr. Andrew N. (Drew) Schiff, M.D.
Independent Director
Independent Director
13.96K
+52.29%
Mr. Kevin Balthaser
Mr. Kevin Balthaser
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Neal S. Walker
Dr. Neal S. Walker
Non-Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Non-Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Hugh M. Davis, Ph.D.
Dr. Hugh M. Davis, Ph.D.
President, Chief Operating Officer, Director
President, Chief Operating Officer, Director
--
--
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. James (Jim) Loerop
Mr. James (Jim) Loerop
Chief Business Officer
Chief Business Officer
103.31K
+21.18%
Mr. Christopher P. Molineaux
Mr. Christopher P. Molineaux
Lead Independent Director
Lead Independent Director
57.96K
+9.02%
Mr. William Douglas Humphries
Mr. William Douglas Humphries
Independent Director
Independent Director
33.52K
+16.68%
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Independent Director
Independent Director
21.75K
+28.26%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
17.32K
+38.27%
Dr. Andrew N. (Drew) Schiff, M.D.
Dr. Andrew N. (Drew) Schiff, M.D.
Independent Director
Independent Director
13.96K
+52.29%
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2018
業務USD
名稱
營收
佔比
Licensing
1.33M
75.13%
Laboratory Research Revenue
442.00K
24.87%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
Licensing
1.33M
75.13%
Laboratory Research Revenue
442.00K
24.87%
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
BML Capital Management LLC
13.15%
Adage Capital Management, L.P.
8.89%
Vivo Capital, LLC
8.21%
The Vanguard Group, Inc.
6.15%
BlackRock Institutional Trust Company, N.A.
4.57%
其他
59.03%
持股股東
持股股東
佔比
BML Capital Management LLC
13.15%
Adage Capital Management, L.P.
8.89%
Vivo Capital, LLC
8.21%
The Vanguard Group, Inc.
6.15%
BlackRock Institutional Trust Company, N.A.
4.57%
其他
59.03%
股東類型
持股股東
佔比
Investment Advisor
31.26%
Hedge Fund
25.11%
Venture Capital
13.67%
Investment Advisor/Hedge Fund
12.35%
Research Firm
4.05%
Individual Investor
2.69%
Pension Fund
0.32%
Bank and Trust
0.10%
Insurance Company
0.03%
其他
10.43%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
305
94.11M
86.87%
-35.53M
2025Q2
322
99.59M
91.98%
-38.98M
2025Q1
348
97.22M
89.83%
-39.83M
2024Q4
345
91.46M
84.84%
-21.09M
2024Q3
339
54.07M
75.01%
-55.64M
2024Q2
343
56.87M
79.07%
-55.28M
2024Q1
324
57.53M
81.03%
-59.90M
2023Q4
334
60.83M
85.72%
-31.33M
2023Q3
329
72.95M
103.11%
-12.25M
2023Q2
327
74.07M
104.78%
-6.71M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BML Capital Management LLC
14.25M
13.15%
--
--
Jun 30, 2025
Adage Capital Management, L.P.
9.63M
8.89%
--
--
Jun 30, 2025
Vivo Capital, LLC
8.89M
8.21%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
6.66M
6.15%
+1.69M
+34.04%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.95M
4.57%
+3.73M
+304.49%
Jun 30, 2025
Rock Springs Capital Management LP
4.77M
4.4%
-277.00K
-5.49%
Jun 30, 2025
Decheng Capital LLC
4.04M
3.73%
--
--
Jun 30, 2025
Millennium Management LLC
3.84M
3.54%
-1.71M
-30.77%
Jun 30, 2025
Morgan Stanley & Co. LLC
3.53M
3.26%
+1.12M
+46.64%
Jun 30, 2025
D. E. Shaw & Co., L.P.
2.80M
2.58%
-144.23K
-4.90%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Invesco NASDAQ Future Gen 200 ETF
0.48%
iShares Micro-Cap ETF
0.03%
ProShares UltraPro Russell2000
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
查看更多
Invesco NASDAQ Future Gen 200 ETF
佔比0.48%
iShares Micro-Cap ETF
佔比0.03%
ProShares UltraPro Russell2000
佔比0.01%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.01%
iShares Russell 2000 Value ETF
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
iShares Russell 2000 ETF
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
